Stock Price
22.98
Daily Change
1.14%
Yearly
-49.58%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Array Technologies Inc 22.98 0.26 1.14% -49.58%
Astrazeneca 55.60 -0.99 -1.74% 5.02%
Bristol-Myers Squibb 54.70 -1.84 -3.25% -12.35%
Eli Lilly 255.73 -4.64 -1.78% 75.58%
Novartis 80.34 -0.37 -0.45% -11.55%

Indexes Price Day Year
US2000 2252 5.62 0.25% 23.72%
NASDAQ 15797 305.64 1.97% 29.50%

Array Technologies Inc
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Companys wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.